Skip to main content
Plastic bottles
Symbol image. Source: Anzhela - stock.adobe.com

News categories: Honors & Funding

Effects of “Forever Chemicals” on the Immune System

Dr. Lorenzo Bonaguro from the German Center of Neurodegenerative Dieseases (DZNE) has been awarded a Starting Grant from the European Research Council (ERC) totaling about 1.5 million euros to investigate the influence of the ubiquitous PFAS chemicals on the immune system. His research will utilize so-called organoids and cutting-edge analysis methods.

Since their invention in the 1950s, thousands of different substances from the category of per- and polyfluorinated alkyl compounds (PFAS) have been developed. Due to their water and fat-repellent properties they are used in countless products like cosmetics, medical devices, clothes and anti-adherent coatings. In addition to their basic chemical structure, the compounds have something else in common: They are almost unbreakable and therefore referred to as “forever chemicals”. Given the widespread presence, their impact on humans is much discussed. “PFAS have been found in the blood of people and there is evidence that chronic exposure even to low levels can pose a health risk, because these chemicals tend to accumulate in the organism,” explains Dr. Lorenzo Bonaguro, a scientist working in DZNE’s “Systems Medicine” research area. “Therefore, I want to assess how PFAS affect the immune system, which is crucial for human health. In fact, I suspect that these chemicals may interfere with the function of the immune system and prevent it from responding appropriately to hazards.”

 

Focus on low levels

Existing toxicity screenings mostly examined the acute effects of high PFAS concentrations. In view of this, the Bonn scientist wants to break new ground. “My research will focus on the effects of low, allegedly harmless concentrations over longer periods of time. This aspect is largely unexplored. PFAS are the subject of much debate. I would like to contribute to resolving the current controversies with reliable data,” he says. “This project can help understand and better manage the effects of PFAS. It could also contribute to new approaches for testing the biological activity at low concentrations of other pollutants.”

 

Tiny tissue samples

The project is based on studies of “organoids” derived from human secondary lymphoid organs, such as tissue from tonsils, and on studies in mice. The research will be undertaken by Bonaguro with a handful of collaborators. “Our organoids are tiny, albeit highly complex tissue cultures that reproduce key features of the human immune system. In particular, they allow to study the behavior of so-called B cells and T cells, which are essential components of the adaptive immune system.” These organoids and also the mice will be exposed to different types of PFAS. “We will explore PFAS-related alterations down to the molecular level. For this, we apply advanced methods such as single-cell transcriptomics. This technology allows to generate a kind of molecular fingerprint of the immune cells reflective of status of individual cells. This generates enormous amount of data that we will analyze with modern bioinformatics approaches.”

 

Reaction to antigens

Bonaguro’s interests include which immune cells are most sensitive to PFAS and whether these chemicals hamper the ability of immune system to respond to “antigenic stimulation”, that is, to substances that are foreign to the organism. This response is critical for both the functioning of vaccines as well as for fighting pathogens. “We will also study potential measures to combat negative impacts and examine whether long-term effects persist after PFAS have been removed from the environment,” the scientist says. “Taken together, the project will provide a comprehensive overview of the consequences of PFAS exposure. In the long term, beyond the current project, I would like to validate these studies in humans.”

Related news

News Icon

News categories: Honors & Funding

Acute lymphoblastic leukemia in children

Acute lymphoblastic leukemia (ALL) is the most common cancer in children and poses a significant threat to health. The joint research project "EDI-4-ALL" (Early detection and interception for acute lymphoblastic leukemia) aims at the development of new analysis tools for the early detection of a genetic predisposition to ALL in newborns. The project is a joint endeavour by leading scientists from the Universities of Düsseldorf, Gießen and Bonn, the Charité Berlin and Zytovision, under participation of Prof. Alksandra Pandyra. The project is funded with a total of 2.6 million Euros by the BMBF.
View entry
Cummings Center announcment group photo

News categories: Honors & Funding

Cooperation with the Cumming Global Centre

The Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre) and the University of Bonn have today announced Bonn-Cumming Host-Directed Pandemic Therapeutics Research Program (“the partnership”) to fund groundbreaking research into early immunity to develop novel targets for therapeutics for pathogens of pandemic potential. The funding volume amounts to 6 million euros, with a perspective of up to 40 million euros. A large part comes from the philanthropic billionaire Geoff Cumming.
View entry
Csm Bradke header 498bf3128b

News categories: Honors & Funding

Berlin-Brandenburg Academy of Science Honors Bonn Neurobiologist

Neurobiologist Frank Bradke, a research group leader at DZNE and professor at the University of Bonn, has been awarded the 50,000 euro Academy Prize of the Berlin-Brandenburg Academy of Sciences and Humanities. The award recognizes his outstanding scientific accomplishments in the field of neuronal development and regeneration. With his studies, the Bonn scientist, who focuses on fundamental mechanisms, aims to pave the way for a better treatment of spinal cord injuries. In recent years, Bradke has already been recognized with several awards for his exceptional research.
View entry

Back to the news overview